Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014

Date: May 21, 2014
Pages: 103
Price:
US$ 2,500.00 US$ 1,875.00
Offer valid until December 31, 2016!
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T54F3E1F8CEEN
Leaflet:

Download PDF Leaflet

Summary

GlobalData's clinical trial report, “Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014' provides data on the Transitional Cell Cancer (Urothelial Cell Cancer) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Transitional Cell Cancer (Urothelial Cell Cancer). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Transitional Cell Cancer (Urothelial Cell Cancer). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Introduction
Transitional Cell Cancer (Urothelial Cell Cancer)
Report Guidance
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Unaccomplished Trials of Transitional Cell Cancer (Urothelial Cell Cancer)
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials
Prominent Drugs
Clinical Trial Profiles
Clinical Trial Overview of Top Companies
Eli Lilly and Company
Clinical Trial Overview of Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
Novartis AG
Clinical Trial Overview of Novartis AG
Bristol-Myers Squibb Company
Clinical Trial Overview of Bristol-Myers Squibb Company
Pfizer Inc.
Clinical Trial Overview of Pfizer Inc.
AstraZeneca PLC
Clinical Trial Overview of AstraZeneca PLC
Sanofi
Clinical Trial Overview of Sanofi
Laboratoires Pierre Fabre SA
Clinical Trial Overview of Laboratoires Pierre Fabre SA
Oncogenex Pharmaceuticals, Inc.
Clinical Trial Overview of Oncogenex Pharmaceuticals, Inc.
Amgen Inc.
Clinical Trial Overview of Amgen Inc.
Clinical Trial Overview of Top Institutes / Government
National Cancer Institute
Clinical Trial Overview of National Cancer Institute
Memorial Sloan Kettering Cancer Center
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center
European Organization for Research and Treatment of Cancer
Clinical Trial Overview of European Organization for Research and Treatment of Cancer
The University of Texas M. D. Anderson Cancer Center
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
University of Michigan
Clinical Trial Overview of University of Michigan
Southwest Oncology Group
Clinical Trial Overview of Southwest Oncology Group
The University of Chicago
Clinical Trial Overview of The University of Chicago
Fox Chase Cancer Center
Clinical Trial Overview of Fox Chase Cancer Center
Gynecologic Oncology Group
Clinical Trial Overview of Gynecologic Oncology Group
Five Key Clinical Profiles
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source

LIST OF TABLES

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Suspended Clinical Trials, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Withdrawn Clinical Trials, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Terminated Clinical Trials, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Laboratoires Pierre Fabre SA, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Oncogenex Pharmaceuticals, Inc., 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Chicago, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fox Chase Cancer Center, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Gynecologic Oncology Group, 2014*

LIST OF FIGURES

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase (%), 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
GlobalData Methodology
Skip to top


Ask Your Question

Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: